SUNNYVALE, Calif., July 14, 2015 /PRNewswire/ -- Accuray
Incorporated (Nasdaq: ARAY) announced today that studies on the
clinical use of the TomoTherapy® System continue to
demonstrate its mainstream use and the benefits of its
gold-standard treatment planning and delivery capabilities. More
than 30 studies were presented during poster or oral sessions at
the 57th Annual Meeting of the American Association of Physicists
in Medicine (AAPM) held in Anaheim,
California July 12 –
July 16, 2015.
For more information on the TomoTherapy System, visit
http://www.accuray.com/solutions/treatment-planning/tomotherapy-treatment-planning-system.
Almost 13 years since commercial launch of the original
TomoTherapy System, customers continue to explore the boundaries of
clinical utilization for this innovative tool used when radiation
is indicated to treat routine to complex cancer cases. Research
highlights include:
Targeted treatment minimizes impact of radiation on
surrounding healthy tissue.
- Researchers at the University of
Arkansas for Medical Sciences and UT Southwestern Medical
Center presented the first clinical applications and associated
dosimetric results of TomoHelical™ based spatially fractionated
radiotherapy (HT-GRID) for deep seated tumors. Ten previously
treated GRID patients were selected and each case was re-planned
either in HT-GRID or LINAC-GRID, using the same prescribed dose.
While the doses to organs at risk were comparable between the
HT-GRID and LINAC-GRID, HT-GRID was able to better spare some
critical structures.
Data underscore the benefits of the TomoTherapy System for
lung cancer patients.
- For patients with locally advanced non-small cell lung cancer
(LA-NSCLC), characteristics of TomoHelical™ and TomoDirect™ IMRT
plans were compared with conventional IMRT plans. Results showed
that both the TomoHelical and TomoDirect IMRT plans provided better
target coverage when compared to conventional IMRT plans. Further,
TomoHelical plans had better sparing effect than IMRT on organs at
risk (OAR) including the spinal cord and heart, while radiation
dose to the esophagus was significantly lower in TomoDirect plans
than IMRT plans. Research was conducted at Samsung Medical
Center.
Study reinforces TomoTherapy System use for intracranial
radiosurgery.
- Researchers at Clinica Luganese in Switzerland evaluated the TomoHDA™ System's
ability to deliver intracranial radiosurgery. Using a pig cadaver
cranium, the accuracy of registration to bone, the sensitivity of
MVCT imaging to position offsets, and end-to-end delivery precision
were assessed. Results indicate the system provides sub-millimeter
accuracy and is a viable option for intracranial radiosurgery.
TomoTherapy System treatment plans demonstrate advantages in
rare cancers.
- A study conducted at UCLA evaluated
the correlation between improved clinical outcomes versus required
treatment dose for adjuvant mesothelioma radiotherapy with either
the TomoTherapy System or conventional 3D techniques. Results
showed the TomoTherapy® System provided dramatically
better target coverage and less heterogeneity, even for large and
irregular treatment sites, while providing better sparing of the
cord and esophagus, and without any increase in radiation
pneumonitis. As superior local control probability is closely
associated with improved target coverage, use of the TomoTherapy
System results in significantly better local control over
traditional 3D techniques for mesothelioma.
"The TomoTherapy treatment planning system has set the standard
for the radiation therapy industry, enabling clinicians to create
precise treatment plans for a wide variety of clinical applications
quickly, easily and intuitively," said Calvin Maurer, Ph.D., vice president and chief
technology officer at Accuray. "Data presented at AAPM further
demonstrate the system's treatment plans routinely deliver a
homogenous dose distribution to the target with excellent
conformality and sparing of OARs for a broad range of tumor
types."
Educational Event
Accuray hosted an educational symposium titled, "Precision in
Practice™ with Accuray Technology" featuring Sharon Qi, Ph.D.,
DABR, Assistant Professor, Division of Medical Physics,
University of California Los Angeles
Center for Radiation Oncology, and Dylan
Casey, Ph.D., Manager, R&D Physics, Accuray
Incorporated, in addition to two invited presenters on the
CyberKnife® System. Dr. Qi discussed the center's
experience using TomoTherapy System treatment plans, providing a
comparative Pareto analysis, and Dr. Casey shared information about
the system's new Delivery Analysis software.
About the TomoTherapy System
The TomoTherapy System is the only radiation system specifically
designed for image-guided intensity-modulated radiation therapy
(IMRT). Based on a CT scanner platform, the system provides
continuous delivery of radiation from 360 degrees around the
patient, or delivery from clinician-specified beam angles. These
unique features, combined with daily 3D image guidance, enable
physicians to deliver highly accurate, individualized dose
distributions which precisely conform to the shape of the patient's
tumor while minimizing dose to normal, healthy tissue, resulting in
fewer side effects for patients. The TomoTherapy System is capable
of treating all standard radiation therapy indications including
breast, prostate, lung and head and neck cancers, in addition to
complex treatments such as total marrow irradiation.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
tumor treatment solutions that set the standard of care with the
aim of helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient outcomes and Accuray's leadership
position in radiation oncology innovation and technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from
expectations, including but not limited to the risks detailed under
the heading "Risk Factors" in the company's report on Form 10-K,
filed on August 29, 2014, the
company's reports on Form 10-Q, filed on November 7, 2014, February
6, 2015 and May 7, 2015, and
the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-tomotherapy-system-data-presented-at-leading-scientific-industry-meeting-300112598.html
SOURCE Accuray Incorporated